drug:cagrisema

CagriSema underperforms in trial

We take a look at the recent results for CagriSema, and see how it tracks against other GLP1s

17 Aug 2025 — 1 min read

We’ve covered the combination of Semaglutide and Cagrilinitide (“CagriSema”) in the past, the results from the REDEFINE-1 clinical trial:

Unfortunately, the positive results of CagriSema were overshadowed by other factors affecting Novo Nordisk.

This time, there’s REDEFINE-2’s results are out, and while they’re objectively good for weight loss they fall short of the results of REDEFINE-1:

Want to read more of our break down on CagriSema's performance, and how a new pill GLP1 could actually be better than injected CagriSema?

The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:

Recent reports of kidney injuries have caused a change in requirements for GLP1 labeling. We dive into the actual risk and what you can do about it.

Trulicity and Mounjaro go head to head, in a clinical trial that finally puts to bed the question of which is better.

GLP1s might be covered under Medicare/medicaid again. The Trump administration introduces a new experiment under the CMMI.

Reports of combining GLP1s with Phentermine suggest superior results. What is Phentermine and how can it be used with GLP1s?

Read more